Developmental medico-life-sciences, Год журнала: 2024, Номер 1(10), С. 4 - 22

Опубликована: Дек. 13, 2024

Ovarian cancer is one of the most aggressive and deadly gynaecological malignancies remains frequently diagnosed at advanced stages because its asymptomatic progression inherent limitations current diagnostic tests. Nanoenzymes (a class nanotechnology-based artificial enzymes) have great promise in addressing these challenges. greatly improve sensitivity specificity biosensors including optical electrochemical systems, with real-time high-precision detection key biomarkers such as CA-125, HE4, mesothelin. The high accuracy biosensors, fluorescence surface plasmon resonance (SPR) based technologies, for early-stage diagnosis, cost-effective, portable, ultra-low limits make them attractive alternatives. Nanoenzyme-based drug delivery systems like liposomes, polymeric micelles, Nanocapsules therapeutic outcomes by allowing targeted transport to tumor tissues, reducing systemic toxicity, overcoming resistance treatment. PEGylated liposomal doxorubicin (Doxil), a formulation, has been shown enhanced efficacy platinum-resistant ovarian cancer, reduced adverse effects. Further theranostic applications metallic nanoparticles gold iron oxide can be realized using therapy imaging. These advancements come their challenges, however, biological barriers, scalability before clinical translation. Interdisciplinary research, validation, creation regulatory frameworks safety are needed future progress. offer revolutionize diagnosis treatment potential facilitate early detection, precision, patient outcome while filling huge gaps approaches.

Язык: Английский